U.S. markets open in 6 hours 20 minutes

Actinium Pharmaceuticals, Inc. (ATNM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
8.26-0.16 (-1.90%)
At close: 4:00PM EDT

Actinium Pharmaceuticals, Inc.

275 Madison Avenue
7th Floor
New York, NY 10016
United States
646 677 3870
http://www.actiniumpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees32

Key Executives

NameTitlePayExercisedYear Born
Mr. Sandesh C. Seth M.B.A., M.S., MBAChairman & CEO893.19kN/A1964
Mr. Steven O'Loughlin BSCFO & Corp. Sec.420kN/A1986
Dr. Dale L. Ludwig Ph.D.Chief Scientific & Technology Officer480kN/A1962
Dr. Mark S. BergerChief Medical Officer515kN/A1955
Dr. David GouldSr. VP of Corp. Devel. & Corp. AffairsN/AN/AN/A
Dr. Bernie CunninghamExec. Director of Clinical Supply Chain & Logistics and CMC Project ManagementN/AN/AN/A
Dr. Qing LiangVP & Head of Radiation SciencesN/AN/AN/A
Dr. Robert N. Daly M.S., Ph.D.VP & Head of Clinical OperationsN/AN/AN/A
Dr. Mamata GokhaleVP & Global Head of Regulatory AffairsN/AN/AN/A
Dr. Avinash DesaiExec. VP of Clinical Devel., Operations & Medical AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.

Corporate Governance

Actinium Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.